Elevation Oncology Inc
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
(0.0% 1d) (-0.2% 1m) (124.0% 1y) (0.0% 2d) (0.0% 3d) (-7.2% 7d) (29.15% volume)
Earnings Calendar: 2022-11-04
Market Cap: $ 196,063,993
https://elevationoncology.com
Sec Filling | Patents | 8 employees
Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. The company makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with its peers Elevation Oncology works towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at www.NRG1fusion.com.
treatment cancer
add to watch list Paper trade email alert is off
Press-releases
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Published: 2024-04-09 (Crawled : 01:00) - elevationoncology.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -0.85%
H: 1.5%
C: 0.64%
preclinical for meeting program
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Published: 2024-04-08 (Crawled : 23:00) - biospace.com/
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -3.87%
H: 0.0%
C: 0.0%
preclinical for meeting program
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Published: 2024-03-06 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: 1.71%
H: 2.95%
C: -1.68%
business year financial results
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: 1.71%
H: 2.95%
C: -1.68%
association cancer research preclinical meeting program
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
Published: 2024-03-04 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: 0.4%
H: 1.39%
C: -4.37%
leaders
Elevation Oncology to Participate in Upcoming Investor Conferences
Published: 2024-02-28 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -0.27%
H: 6.76%
C: 4.05%
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Published: 2024-02-22 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -1.44%
H: 5.49%
C: -1.1%
eo-3021 first japan ongoing trial
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
Published: 2024-01-22 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -3.16%
H: 21.22%
C: 15.1%
Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones
Published: 2024-01-05 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: 11.54%
H: 43.94%
C: 32.52%
program
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference
Published: 2023-11-22 (Crawled : 12:30) - prnewswire.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: 1.64%
H: 4.49%
C: -3.51%
conference
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001415889-24-006289 | 4 | 2024-03-04 | 2024-02-29 | Buy | A | 55000 | 55000 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10